AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for ABT-414

The FDA has granted a Rare Pediatric Disease Designation for ABT-414, an investigational antibody drug conjugate (ADC) that focuses on the epidermal growth factor receptor (EGFR), for the potential treatment of pediatric patients with EGFR-amplified Diffuse Intrinsic Pontine Glioma (DIPG). The drug is being developed by Abbvie. And if approved, the drug could be worth hundreds of millions in extra revenue for the company thanks to the priority review voucher program that is given to drugs approved for a pediatric condition.


For more information see here: